Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Exploris 480
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Melanocyte, Skin
SUBMITTER: Lauren Stopfer
LAB HEAD: Forest White
PROVIDER: PXD029884 | Pride | 2023-03-11
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
A375_100nM_1_Targeted.raw | Raw | |||
A375_100nM_3_Targeted.raw | Raw | |||
A375_100nm_2_Targeted.raw | Raw | |||
A375_1uM_1_Targeted.raw | Raw | |||
A375_1uM_2_Targeted.raw | Raw |
Items per page: 5 1 - 5 of 30 |
Stopfer Lauren E LE Rettko Nicholas J NJ Leddy Owen O Mesfin Joshua M JM Brown Eric E Winski Shannon S Bryson Bryan B Wells James A JA White Forest M FM
Proceedings of the National Academy of Sciences of the United States of America 20221201 49
Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma-namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies-may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition (MEKi) alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile chang ...[more]